Core Viewpoint - Tandem Diabetes Care, Inc. reported a quarterly loss of $0.01 per share, outperforming the Zacks Consensus Estimate of a loss of $0.05, marking an earnings surprise of +80.51% compared to a loss of $0.44 per share a year ago [1][2] Financial Performance - The company posted revenues of $290.38 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 5.21% and showing an increase from $252.45 million in the same quarter last year [2] - Over the last four quarters, Tandem Diabetes Care has surpassed consensus revenue estimates four times [2] Stock Performance - Shares of Tandem Diabetes Care have declined approximately 13.8% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current Zacks Rank for the stock is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.45 on revenues of $249.96 million, and for the current fiscal year, it is -$0.99 on revenues of $1.1 billion [7] - The trend of earnings estimate revisions is mixed ahead of the earnings release, which could influence future stock performance [6] Industry Context - The Medical - Instruments industry, to which Tandem Diabetes Care belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

分组1 - Spotify reported quarterly earnings of $5.16 per share, exceeding the Zacks Consensus Estimate of $3.16 per share, and showing a significant increase from $1.88 per share a year ago, representing an earnings surprise of +63.29% [1] - The company generated revenues of $5.27 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.57%, and up from $4.53 billion in the same quarter last year [2] - Over the last four quarters, Spotify has exceeded consensus EPS estimates two times and topped revenue estimates twice [2] 分组2 - The stock has underperformed the market, losing about 28.6% since the beginning of the year, while the S&P 500 has gained 1.7% [3] - The current consensus EPS estimate for the upcoming quarter is $3.05 on revenues of $5.24 billion, and for the current fiscal year, it is $13.59 on revenues of $22.41 billion [7] - The Zacks Industry Rank places the Internet - Software sector in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

分组1 - Coursera reported quarterly earnings of $0.06 per share, matching the Zacks Consensus Estimate, but down from $0.08 per share a year ago, resulting in an earnings surprise of -5.21% [1] - The company posted revenues of $196.9 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 2.67% and up from $179.18 million year-over-year [2] - Coursera has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed, losing about 17.5% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the upcoming quarter is $0.11 on revenues of $190.9 million, and for the current fiscal year, it is $0.47 on revenues of $798.29 million [7] - The Zacks Industry Rank indicates that the Technology Services sector is in the bottom 39% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

分组1 - COPT Defense reported quarterly funds from operations (FFO) of $0.7 per share, exceeding the Zacks Consensus Estimate of $0.68 per share, and up from $0.65 per share a year ago, indicating a positive performance [1][2] - The company achieved revenues of $197.36 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.85% and increasing from $183.43 million year-over-year [3] - COPT Defense has outperformed the S&P 500, with shares rising approximately 11.9% since the beginning of the year compared to the S&P 500's gain of 0.5% [4] 分组2 - The current consensus FFO estimate for the upcoming quarter is $0.67 on revenues of $193.87 million, while the estimate for the current fiscal year is $2.73 on revenues of $787.28 million [8] - The Zacks Industry Rank places the REIT and Equity Trust - Other sector in the bottom 28% of over 250 Zacks industries, suggesting potential challenges for stocks in this category [9] - InvenTrust Properties Corp., another company in the same industry, is expected to report quarterly earnings of $0.45 per share, reflecting a year-over-year change of +4.7% [10]

Core Insights - IDEXX Laboratories, Inc. (IDXX) is scheduled to release its fourth-quarter 2025 results on February 2, before the market opens [1] - The company reported adjusted earnings per share (EPS) of $3.40 in the last quarter, exceeding the Zacks Consensus Estimate by 8.28%, and has consistently beaten estimates over the past four quarters with an average surprise of 7.12% [1] Q4 Estimates - The Zacks Consensus Estimate for fourth-quarter revenues is $1.07 billion, reflecting a 12.2% increase from the previous year [2] - The EPS estimate stands at $2.93, indicating an 11.8% rise year-over-year [2] - Earnings estimates have remained stable at $2.93 over the past 60 days [3] Key Drivers of Performance - The Companion Animal Group (CAG) is expected to maintain its momentum, driven by strong commercial execution and recurring revenues from diagnostics, particularly in the U.S. and international markets [4] - IDEXX VetLab consumables are anticipated to benefit from increased test volumes and higher realized prices [4] - Key innovations such as the IDEXX inVue Dx Analyzer and IDEXX Cancer Dx panel are likely to have seen strong adoption, contributing to increased recurring revenues in Veterinary Software and Services [5] Segment Performance - CAG revenues are projected to grow by 12.7% year-over-year in Q4 2025 [7] - The Water segment is expected to see revenues increase by 7.8% year-over-year, supported by higher prices and volumes [10] - The Livestock, Poultry and Dairy (LPD) division is also anticipated to experience a 7.8% year-over-year revenue increase, driven by higher test volumes and prices across various regions [11] Earnings Model Insights - IDEXX Laboratories has an Earnings ESP of 0.00%, indicating no expected surprise in earnings [12] - The company currently holds a Zacks Rank of 2 (Buy) [13]

Core Viewpoint - The Bank of New York Mellon Corporation (BK) is expected to report increased quarterly revenues and earnings for the fourth quarter and 2025 results on January 13, before market open [1][9]. Financial Performance - In the last reported quarter, BK's earnings exceeded the Zacks Consensus Estimate, driven by a rise in fee revenues and net interest income (NII), along with a provision benefit [2]. - The consensus estimate for fourth-quarter earnings is $1.97 per share, reflecting a 14.5% increase from the previous year [3]. - The consensus estimate for 2025 earnings is $7.40 per share, indicating a year-over-year growth of 22.7% [4]. Revenue Estimates - The consensus estimate for total investment services fees is $2.61 billion, suggesting a 7.1% increase from the year-ago quarter [5]. - Financing-related fees are estimated at $56 million, indicating a 5.7% year-over-year rise [5]. - The total fees and other revenues are projected to be $3.85 billion, reflecting a 5.3% increase from the previous year [7]. Net Interest Income (NII) - The consensus estimate for NII is $1.27 billion, indicating a 6.5% year-over-year rise [10]. - Despite recent interest rate cuts, NII is expected to increase due to robust loan growth and stable funding costs [9][10]. Expense Outlook - Overall expenses are anticipated to rise due to inflationary pressures and technology upgrades, with fourth-quarter non-interest expenses estimated at $3.34 billion, suggesting a marginal year-over-year decline [11]. - Management expects 2025 expenses to increase by 3% from $12.5 billion in 2024, driven by higher revenue-related expenses [12]. Earnings Surprise Potential - BK has a strong earnings surprise history, with an average beat of 9.1% over the trailing four quarters [3]. - The Earnings ESP for BK is +1.25%, indicating a high likelihood of beating the Zacks Consensus Estimate [13].

Core Viewpoint - Donaldson Company, Inc. is preparing to release its earnings report, with Wall Street expecting growth in earnings, although analyst opinions are mixed, particularly with Nathan Jones from Stifel Nicolaus setting a lower price target of $51 [1] Group 1: Price Target Trends - The consensus price target for DCI has remained stable at an average of $90 over the past month and the last quarter, indicating no significant changes in analysts' views on the company's performance [2] - A year ago, the average price target was $83.67, reflecting a positive trend with a 7.6% increase over the year, which may be due to the company's performance or favorable market conditions [3] Group 2: Upcoming Earnings Report - Donaldson's earnings conference call is scheduled for December 4, 2025, which will provide further insights into the company's performance, and investors can access the live webcast via the company's Investor Relations website [4] - The stable price target in recent months, along with the increase from last year, suggests a cautiously optimistic outlook on DCI's future prospects [4]

Core Insights - Howard Hughes Holdings (HHH) is expected to report quarterly earnings of $1.56 per share, reflecting a year-over-year decline of 20% [1] - Revenue projections stand at $331.53 million, indicating a slight increase of 1.3% from the previous year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, suggesting analysts have reassessed their initial projections [1] Revenue Estimates - Analysts forecast 'Revenues- Master Planned Community land sales' to reach $199.43 million, a change of +0.6% from the year-ago quarter [4] - 'Revenues- Operating Assets Segment' is expected to arrive at $114.18 million, indicating a change of +0.1% from the prior-year quarter [4] - 'Revenues- Master Planned Communities Segment' is projected to be $217.38 million, reflecting a change of +2.2% from the year-ago quarter [4] Stock Performance - Shares of Howard Hughes Holdings have decreased by -5.2% over the past month, contrasting with a +1.3% increase in the Zacks S&P 500 composite [5] - HHH holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [5]

Core Insights - C4 Therapeutics, Inc. reported a quarterly loss of $0.44 per share, which was better than the Zacks Consensus Estimate of a loss of $0.47, representing an earnings surprise of +6.38% [1] - The company generated revenues of $11.23 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 72.77%, although this was a decline from $15.36 million in the same quarter last year [2] - C4 Therapeutics shares have underperformed, losing approximately 34.2% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $9.5 million, and for the current fiscal year, it is -$1.46 on revenues of $29.7 million [7] - The estimate revisions trend for C4 Therapeutics was favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which C4 Therapeutics belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Capricor Therapeutics (CAPR) shares increased by 12% to close at $6.92, following a 14.3% decline over the past four weeks, indicating a significant turnaround in investor sentiment [1][2]. Company Performance - The recent rise in CAPR shares is linked to the company's regulatory advancements and optimism regarding upcoming clinical milestones, particularly after management confirmed FDA alignment on trial endpoints [2]. - The company is projected to report a quarterly loss of $0.54 per share, reflecting a year-over-year decrease of 42.1%, while revenues are expected to reach $2.4 million, marking a 6.2% increase from the previous year [3]. - The consensus EPS estimate for Capricor has remained stable over the last 30 days, suggesting that the stock's price movement may not sustain without changes in earnings estimate revisions [4]. Industry Context - Capricor operates within the Zacks Medical - Products industry, where LeMaitre Vascular (LMAT) is another player, having closed at $88.87 with a 0.8% decline in the last trading session [5]. - LeMaitre's consensus EPS estimate has increased by 2.9% over the past month to $0.57, representing a year-over-year change of 16.3% [6].